HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials - PubMed
14 hours ago
- #HIF-2α inhibitor
- #kidney cancer
- #clinical trials
- Two phase III trials, LITESPARK-022 and LITESPARK-011, show benefits of HIF-2α inhibitor belzutifan in clear cell renal cell carcinoma.
- Combining belzutifan with PD-1 inhibitor pembrolizumab reduced disease recurrence risk by 28% and improved disease-free survival compared to pembrolizumab alone.
- For patients with recurring disease post-immunotherapy, belzutifan plus VEGFR inhibitor lenvatinib outperformed cabozantinib in overall response, progression-free survival, and response duration.